Consequently, currently, there are no approved PTP1B inhibitors [20], despite the high demand for the effective treatment of the diseases associated with insulin and leptin resistance (T2DM, metabolic syndrome, and obesity). This evidence concerns the gene INS and obesity due to melanocortin 4 receptor deficiency.